1-(1-甲基环己基)乙酮 | 2890-62-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(1-甲基环己基)乙酮
• 英文名称: methyl 1-methylcyclohexyl ketone
• 英文别名: 1-(1-methylcyclohexyl)ethanone；1-(1-methylcyclohexyl)ethan-1-one
• CAS: 2890-62-2
• 化学式: C₉H₁₆O
• 分子量: 140.225
• InChiKey: UBMBCDFRVPGSSQ-UHFFFAOYSA-N

物化性质

• 熔点：
  65-66 °C(Solv: hexane (110-54-3))
• 沸点：
  186.2°C (estimate)
• 密度：
  0.9504

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 储存条件：
  室温和干燥环境

反应信息

• 作为反应物：
  描述：

  1-(1-甲基环己基)乙酮 在 kieselguhr 、 乙醚 、 镍 作用下， 生成 1-异丙基-1-甲基环己烷
  参考文献：
  名称：

  Study in the Terpene Series. XXII.^1a Synthesis, Physical Constants and Catalytic Dehydrogenation of 1-Methyl-1-ethyl-, 1-Methyl-1-n-propyl- and 1-Methyl-1-isopropylcyclohexane^1b

  摘要：

  DOI：

  10.1021/ja01615a044
• 作为产物：
  描述：

  异亚丙基环己烷 在 盐酸 、 p-nitrobenzenesulfonyl azide 作用下， 生成 1-(1-甲基环己基)乙酮
  参考文献：
  名称：

  Reaction of p-nitrobenzenesulfonyl azide with alkylidenecycloalkanes

  摘要：

  DOI：

  10.1021/jo00315a023

文献信息

• Six- and Eightfold Palladium-Catalyzed Cross-Coupling Reactions of Hexa- and Octabromoarenes
  作者：Baldur Stulgies、Peter Prinz、Jörg Magull、Karsten Rauch、Kathrin Meindl、Stephan Rühl、Armin de Meijere

  DOI：10.1002/chem.200400723

  日期：2005.1

  Palladium-catalyzed sixfold coupling of hexabromobenzene (20) with a variety of alkenylboronates and alkenylstannanes provided hexaalkenylbenzenes 1 in up to 73 % and 16 to 41 % yields, respectively. In some cases pentaalkenylbenzenes 21 were isolated as the main products (up to 75 %). Some functionally substituted hexaalkenylbenzene derivatives containing oxygen or sulfur atoms in each of their six

  钯催化六溴代苯（20）与各种烯基硼酸酯和烯基锡酮的六重偶联分别提供了六烯基苯1，产率分别高达73％和16％至41％。在某些情况下，五烯基苯21被分离为主要产物（最高含量为75％）。还已经制备了一些在其六个臂中的每个臂中含有氧或硫原子的官能取代的六烯基苯衍生物（16％至24％的产率）。较少空间阻碍的2,3,6,7,10,11-六溴代三亚苯基（24）的六倍偶联以93％的收率得到了所需的六（3,3-二甲基-1-丁烯基）三亚苯基（25）。八溴萘（26）的首次成功的交叉偶联反应以21％的收率得到了八-（3,3-二甲基-1-丁烯基）萘（27）。晶体结构分析表明，根据取代基的性质，这六个臂与1a和1i一样全部位于中心苯环的同一侧，从而使它们成杯形分子，或者在1h和23中交替地位于中心平面的上方和下方。在27中， C-1,4,6,7的四个臂向下，其他的臂向上，反之亦然。催化氢化后，1 a产生89％的六（叔
• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20130183269A1

  公开（公告）日：2013-07-18

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组成物，以及抑制NS5A蛋白功能的方法。
• PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES
  申请人：Blumberg Laura Cook

  公开号：US20110319422A1

  公开（公告）日：2011-12-29

  The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.

  该发明提供了一种持续释放内酰胺、亚酰胺、酰胺、磺胺、碳酸酯或尿素含有母药的方法，通过向患者施用该发明的一种前药化合物的有效量，在向患者施用后，从前药中释放母药是持续释放的。适用于该发明方法的前药化合物是母药的不稳定结合物，通过羰基连接的前药基团进行衍生化。该发明的前药化合物可用于治疗任何需要内酰胺、亚酰胺、酰胺、磺胺、碳酸酯或尿素含有母药作为治疗的情况。
• THERAPEUTIC AGENT FOR DIABETES
  申请人：Japan Tobacco Inc.

  公开号：EP0885869A1

  公开（公告）日：1998-12-23

  A therapeutic agent for diabetes, which comprises a compound of the formula [I] wherein Xis a group of the formula wherein R4 and R5 are the same or different and each is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, and R6 is a hydrogen atom or an amino-protecting group; R1 is an optionally substituted alkyl having 1 to 5 carbon atoms, an optionally substituted alkenyl having 2 to 6 carbon atoms and the like, R2 is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, R2' is a hydrogen atom, and R3 is an optionally substituted alkyl having 1 to 5 carbon atoms and the like, a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof. The compound of the present invention shows superior blood sugar decreasing action on the state of hyperglycemia, but does not affect the blood sugar when it is in the normal range or in the hypoglycemic state, which means that it is free of serious side effects such as hypoglycemia. Therefore, the compound of the present invention is useful as a therapeutic drug for diabetes and also useful as a preventive of the chronic complications of diabetes.

  用于治疗糖尿病的疗法剂，包括公式[I]的化合物 其中 X是公式的组 其中R4和R5相同或不同，每个都是氢原子，可选地取代的具有1至5个碳原子的烷基等等，R6是氢原子或氨基保护基团；R1是具有1至5个碳原子的可选取代烷基，具有2至6个碳原子的可选取代烯基等等，R2是氢原子，具有1至5个碳原子的可选取代烷基等等，R2'是氢原子，R3是具有1至5个碳原子的可选取代烷基等等，其前药，药用可接受盐，水合物和溶剂化物。 本发明的化合物在血糖升高状态下表现出优越的降血糖作用，但在正常范围或低血糖状态下不影响血糖，这意味着它没有低血糖等严重副作用。因此，本发明的化合物作为治疗糖尿病的药物很有用，也用作预防糖尿病慢性并发症。
• Direct Decarboxylative–Decarbonylative Alkylation of α-Oxo Acids with Electrophilic Olefins via Visible-Light Photoredox Catalysis
  作者：Jian-Qiang Chen、Rui Chang、Yun-Long Wei、Jia-Nan Mo、Zhu-Yin Wang、Peng-Fei Xu

  DOI：10.1021/acs.joc.7b02628

  日期：2018.1.5

  The decarbonylation of primary, secondary, and tertiary alkyl-substituted acyl radicals has been investigated through photoredox catalysis. A series of quaternary carbons and γ-ketoesters have been directly constructed by the photoredox 1,4-conjugate addition of the corresponding alkyl ketoacids with electrophilic alkenes. And, the tertiary alkyl ketoacids have proved to be good precursors of tertiary

  已经通过光氧化还原催化研究了伯，仲和叔烷基取代的酰基的脱羰作用。通过将相应的烷基酮酸与亲电烯烃进行光氧化还原1，4-共轭加成反应，可以直接构建一系列的季碳和γ-酮酸酯。并且，叔烷基酮酸已被证明是叔烷基自由基的良好前体。